337 related articles for article (PubMed ID: 30312578)
1. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
[TBL] [Abstract][Full Text] [Related]
2. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
3. Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression.
Mansukhani SA; Hutchinson AK; Neustein R; Schertzer J; Allen JC; Hubbard GB
Ophthalmol Retina; 2019 May; 3(5):436-443. PubMed ID: 31044736
[TBL] [Abstract][Full Text] [Related]
4. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
5. Findings in Persistent Retinopathy of Prematurity.
Warren CC; Young JB; Goldberg MR; Connor TB; Kassem IS; Costakos DM
Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):497-503. PubMed ID: 30021036
[TBL] [Abstract][Full Text] [Related]
6. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
[No Abstract] [Full Text] [Related]
7. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
[TBL] [Abstract][Full Text] [Related]
8. Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect.
Ji MH; Moshfeghi DM; Shields RA; Bodnar Z; Ludwig CA; Callaway NF; Orazi L; Amorelli GM; Lepore D
Eur J Ophthalmol; 2021 Jul; 31(4):2135-2140. PubMed ID: 32722932
[TBL] [Abstract][Full Text] [Related]
9. Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.
Padhi TR; Das T; Rath S; Pradhan L; Sutar S; Panda KG; Modi R; Jalali S
Eye (Lond); 2016 Mar; 30(3):392-9. PubMed ID: 26584796
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection.
Milani AE; Arasteh A; Saeedi-Maleki Z; Niyousha MR; Sahebazamani MA; Brumandpur F
BMC Ophthalmol; 2024 Jun; 24(1):265. PubMed ID: 38907228
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal injection of bevacizumab for retinopathy of prematurity.
Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
[TBL] [Abstract][Full Text] [Related]
12. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
[TBL] [Abstract][Full Text] [Related]
13. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
[TBL] [Abstract][Full Text] [Related]
15. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
17. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA; Wright LM; Young RC; Read SP; Chang EY
Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
[TBL] [Abstract][Full Text] [Related]
18. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.
Isaac M; Tehrani N; Mireskandari K;
Eye (Lond); 2016 Mar; 30(3):333-41. PubMed ID: 26869159
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
20. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
